216 related articles for article (PubMed ID: 29648575)
1. Early evolutionary divergence between papillary and anaplastic thyroid cancers.
Capdevila J; Mayor R; Mancuso FM; Iglesias C; Caratù G; Matos I; Zafón C; Hernando J; Petit A; Nuciforo P; Cameselle-Teijeiro JM; Álvarez C; Recio JA; Tabernero J; Matias-Guiu X; Vivancos A; Seoane J
Ann Oncol; 2018 Jun; 29(6):1454-1460. PubMed ID: 29648575
[TBL] [Abstract][Full Text] [Related]
2. Hobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
Teng L; Deng W; Lu J; Zhang J; Ren X; Duan H; Chuai S; Duan F; Gao W; Lu T; Wu H; Liang Z
Oncotarget; 2017 Mar; 8(13):22023-22033. PubMed ID: 28423545
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional genome landscape comprehensively reveals patterns of spatial gene regulation in papillary and anaplastic thyroid cancers: a study using representative cell lines for each cancer type.
Zhang L; Xu M; Zhang W; Zhu C; Cui Z; Fu H; Ma Y; Huang S; Cui J; Liang S; Huang L; Wang H
Cell Mol Biol Lett; 2023 Jan; 28(1):1. PubMed ID: 36609218
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
5. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
6. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
7. Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor.
Dong W; Nicolson NG; Choi J; Barbieri AL; Kunstman JW; Abou Azar S; Knight J; Bilguvar K; Mane SM; Lifton RP; Korah R; Carling T
Genes Chromosomes Cancer; 2018 Dec; 57(12):645-652. PubMed ID: 30136351
[TBL] [Abstract][Full Text] [Related]
8. Down-Regulation of APTR and it's Diagnostic Value in Papillary and Anaplastic Thyroid Cancer.
Zhang K; Li C; Liu J; Li Z; Ma C
Pathol Oncol Res; 2020 Jan; 26(1):559-565. PubMed ID: 30539519
[TBL] [Abstract][Full Text] [Related]
9. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract][Full Text] [Related]
10. Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis.
Song YS; Jung CK; Jung KC; Park YJ; Won JK
J Korean Med Sci; 2017 Oct; 32(10):1721-1726. PubMed ID: 28875621
[TBL] [Abstract][Full Text] [Related]
11. The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.
Pan Z; Li L; Qian Y; Ge X; Hu X; Zhang Y; Ge M; Huang P
Cancer Biol Ther; 2020 Sep; 21(9):853-862. PubMed ID: 32887540
[TBL] [Abstract][Full Text] [Related]
12. Novel somatic alterations underlie Chinese papillary thyroid carcinoma.
Yang C; Xu W; Gong J; Liu Z; Cui D
Cancer Biomark; 2020; 27(4):445-460. PubMed ID: 32065787
[TBL] [Abstract][Full Text] [Related]
13. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis.
Lan X; Bao H; Ge X; Cao J; Fan X; Zhang Q; Liu K; Zhang X; Tan Z; Zheng C; Wang A; Chen C; Zhu X; Wang J; Xu J; Zhu X; Wu X; Wang X; Shao Y; Ge M
Cancer Sci; 2020 Jun; 111(6):2163-2173. PubMed ID: 32187423
[TBL] [Abstract][Full Text] [Related]
14. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
15. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
16. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch.
Hébrant A; Dom G; Dewaele M; Andry G; Trésallet C; Leteurtre E; Dumont JE; Maenhaut C
PLoS One; 2012; 7(10):e37807. PubMed ID: 23115614
[TBL] [Abstract][Full Text] [Related]
19. Genetic landscape of papillary thyroid carcinoma in the Chinese population.
Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS
J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541
[TBL] [Abstract][Full Text] [Related]
20. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.
Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM
Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
